Research Background

Indirect inguinal hernia (IIH) and undescended testis (UT) are common in male children and are currently treated solely by surgical intervention. These conditions carry significant risks of complications and economic burden, making elucidation of the underlying causes critical. The research team aims to identify genes involved in the formation of the process vaginalis (PV).

Study Design

This prospective cross‑sectional study, initiated on September 9, 2025, will enroll 20 patients with IIH, 20 patients with UT, and 20 patients undergoing circumcision. Process vaginalis tissue excised during surgery, along with adjacent pre‑treatment tissue, will be collected, and blood samples will be obtained. Next‑generation sequencing (NGS) will be used to screen for variants in INSL3, WT1, and GATA6, and quantitative real‑time PCR will validate differential expression at the tissue level.

Current Treatment Landscape

At present, surgical correction remains the sole therapeutic option for IIH and UT, with limited ability to manage recurrence or complications. No pharmacologic or non‑invasive therapies have been developed, imposing a substantial burden on patients and healthcare systems.

Differentiation and Expected Impact

This study represents the first effort to pinpoint specific genes directly implicated in PV formation. If successful, genetic biomarkers could enable early diagnosis and risk stratification, reducing unnecessary surgeries and lowering treatment costs.

Industry Impact and Future Outlook

Elucidating the genetic etiology could provide a foundation for biotech companies to develop pediatric genetic testing kits. In the short term, the primary deliverables will be scientific presentations and patent filings; in the medium to long term, there is potential for expansion of personalized preventive therapeutics and the gene‑based diagnostics market.